×
About 1,125 results

ALLMedicine™ Complex Partial Seizures Center

Research & Reviews  219 results

RNS System RESPONSE Study
https://clinicaltrials.gov/ct2/show/NCT04839601

Apr 14th, 2022 - NeuroPace is sponsoring the RESPONSE Study with the RNS System in individuals age 12 through 17 with partial (focal) onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or mo...

RNS® System Epilepsy PAS
https://clinicaltrials.gov/ct2/show/NCT02403843

Apr 1st, 2022 - NeuroPace, Inc. is sponsoring a post-approval study (PAS) of the RNS System device. The RNS System is the first FDA-approved closed loop responsive neurostimulator designed to reduce the frequency of seizures in individuals with partial onset seiz...

Longstanding Phenytoin Use as a Cause of Progressive Dyspnea.
https://doi.org/10.1016/j.chest.2021.08.079
Chest Walker A, Rupal A et. al.

Feb 9th, 2022 - A 54-year-old South African man with a medical history of type 2 diabetes mellitus, seizure disorder, OSA, and latent TB presented to the ER with gradually progressive dyspnea over months. He also reported occasional dry cough and fatigue at prese...

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
https://clinicaltrials.gov/ct2/show/NCT01140867

Jan 4th, 2022 - The object of this study is to assess the efficacy and safety of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy. Subject takes zonisamide for 16 weeks (4 weeks-titration period, 8 weeks maintenance period). Dose ra...

see more →

Drugs  187 results see all →

Clinicaltrials.gov  12 results

RNS System RESPONSE Study
https://clinicaltrials.gov/ct2/show/NCT04839601

Apr 14th, 2022 - NeuroPace is sponsoring the RESPONSE Study with the RNS System in individuals age 12 through 17 with partial (focal) onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or mo...

RNS® System Epilepsy PAS
https://clinicaltrials.gov/ct2/show/NCT02403843

Apr 1st, 2022 - NeuroPace, Inc. is sponsoring a post-approval study (PAS) of the RNS System device. The RNS System is the first FDA-approved closed loop responsive neurostimulator designed to reduce the frequency of seizures in individuals with partial onset seiz...

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
https://clinicaltrials.gov/ct2/show/NCT01140867

Jan 4th, 2022 - The object of this study is to assess the efficacy and safety of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy. Subject takes zonisamide for 16 weeks (4 weeks-titration period, 8 weeks maintenance period). Dose ra...

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
https://clinicaltrials.gov/ct2/show/NCT00988429

May 19th, 2021 - The study was designed to include 3 parts; only the first part is described in this report. Part I of the study was an international, randomized, placebo-controlled, double-blind, parallel group, multicenter clinical study conducted in 19 countrie...

The Pattern of Pediatric Seizures at Al-Arish Central Hospital - North Sinai
https://clinicaltrials.gov/ct2/show/NCT03374384

Nov 26th, 2019 - A seizure or convulsion is a paroxysmal, time-limited change in motor activity and/or behavior that results from abnormal electrical activity in the brain . The International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy...

see more →

News  31 results

Rosuvastatin-Induced Rhabdomyolysis, Pancreatitis, Transaminitis, and Acute Kidney Injury
https://www.mdedge.com/fedprac/article/248530/diabetes/rosuvastatin-induced-rhabdomyolysis-pancreatitis-transaminitis-and
Brent Wagner, MD, MS, G. Patricia Escobar, DVM et. al.

Nov 10th, 2021 - Attention should be paid to changing a tolerated medication to another within its class. Many drugs approved by the US Food and Drug Administration (FDA), have equivalent therapeutic properties as existing drugs.

FDA Clears First Generic Version of Seizure Drug Sabril (Vigabatrin)
https://www.medscape.com/viewarticle/907809

Jan 16th, 2019 - The US Food and Drug Administration (FDA) has approved the first generic version of the antiseizure medication Sabril (vigabatrin, Lundbeck). Generic vigabatrin (500-mg tablets), made by Teva Pharmaceuticals USA, is indicated as add-on therapy for...

Cenobamate Reduces the Frequency of Partial-Onset Seizures
https://www.mdedge.com/neurology/epilepsyresourcecenter/article/169570/epilepsy-seizures/cenobamate-reduces

Jul 5th, 2018 - LOS ANGELES—Adjunctive treatment with an investigational antiepileptic drug (AED) reduces the median frequency of partial-onset seizures, according to trial results presented at the 70th Annual Meeting of the American Academy of Neurology. “The re.

Drug Deposited Directly Into the Brain Effective in Severe Epilepsy
https://www.medscape.com/viewarticle/889978

Dec 12th, 2017 - WASHINGTON, DC — A microinfusion device that continuously delivers valproate directly to the brain is safe and effective in patients with refractory focal epilepsy, early research shows. Delivery of valproate through the intracerebroventricular de...

Epilepsy: Osmosis Study Video
https://www.medscape.com/viewarticle/881523

Jul 21st, 2017 - What is Epilepsy? Epilepsy is a condition characterized by recurrent and unpredictable seizures. Seizures are characterized by groups of neurons being activated simultaneously, leading to both outward symptoms like muscle jerking and convulsions, ...

see more →

Patient Education  1 results see all →